Relma-cel
ApprovedCell therapy
Relma-cel is one of 102 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Approved.
3
Indications
5
Total Trials
4
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Relma-cel
SShanghai Ming Ju Biotechnology Co., Ltd.
Approved
Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
PEG-Intron
Merck & Co.Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma2 trials
Systemic Lupus Erythematosus2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Relma-cel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details